Alterations in DNA Damage Response, Tumor Mutation Burden and MSI status as Potential Marker of Clinical Benefit From BCG treatment in Nonmuscle Invasive Bladder Cancer

Status

Recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900023938

Enrollment

Unknown

Registered

2019-06-19

Start date

2019-06-20

Completion date

Unknown

Last updated

2019-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nonmuscle Invasive Bladder Cancer

Interventions

Case series:BCG treatment

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. After TURBT surgery, diagnosed as NMIBC patients with intermediate or high risk; 2. Signed the consent agreement, age equal to or above 18 years old; 3. Agree to follow the planed visit, be able to offer the pre-treatment tumor tissue block, and willing to provide follow-up data of recurrent or not within 5 years.

Exclusion criteria

Exclusion criteria: 1. The investigator judged that the patient had other serious illnesses that may affect follow-up and short-term survival, and any medical reasons showed a significant risk of death during the first year study period; 2. Previous diagnosis of any other malignant tumor; 3. After TURBT surgery, diagnosed as non-NMIBC patients or NMIBC patients with low risk; 4. Patients judged by the investigator that is not suitable for enrollment.

Design outcomes

Primary

Measure	Time frame
Recurrent free survival;	—

Countries

China

Contacts

Public ContactShuyin Chen

Shuyin.chen@brbiotech.com+86 13378686952

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026